Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a pioneering biopharmaceutical company, has announced it will release its financial and business results for the fiscal year ended December 31, 2024, on March 17, 2025. The company, known for its innovative use of the ProCellEx® plant cell-based protein expression system, develops and commercializes recombinant therapeutic proteins. Protalix made history by becoming the first company to receive FDA approval for a protein produced through this unique method, setting a new standard for industrial-scale recombinant protein production.

On the announcement date, Protalix management plans to host a conference call at 8:30 a.m. EDT to discuss the financial results and provide updates on recent corporate and regulatory developments. Interested participants can join the call using a toll-free number or through an international line, with call details provided in advance. Additionally, there will be a webcast available for those who prefer online access. The company has requested participants to log in at least 15 minutes beforehand to ensure a smooth connection.

Protalix's notable achievements include the licensing of taliglucerase alfa for Gaucher disease to Pfizer Inc. while retaining rights in Brazil. The company’s second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023, in partnership with Chiesi Farmaceutici S.p.A. Protalix's development pipeline includes promising candidates like PRX-115, targeting uncontrolled gout, and PRX-119, for NETs-related diseases. As it approaches a significant financial disclosure, investor interest in Protalix’s innovative therapeutic developments is expected to grow.

As Protalix BioTherapeutics (NYSE American: PLX) prepares to announce its Fiscal Year 2024 financial results on March 17, 2025, investors should approach this upcoming report with cautious optimism. Protalix's innovative plant cell-based protein expression system, ProCellEx, provides a competitive edge in the biopharmaceutical industry, particularly with its FDA-approved products, taliglucerase alfa and Elfabrio®.

Key points to consider leading into the earnings report include:

1. **Financial Performance:** Investors should closely analyze revenue growth, particularly from Elfabrio which was launched after receiving FDA and EMA approval in May 2023. Any indications of strong market adoption or sales figures will be critical in shaping confidence in Protalix's financial health.

2. **Pipeline Progress:** Protalix's development pipeline, including PRX-115 for uncontrolled gout and PRX-119 directed at NETs-related diseases, is essential for long-term growth prospects. Management's commentary around milestones related to these candidates and any new regulatory progress will be crucial.

3. **Partnerships and Collaborations:** The licensing agreement with Pfizer for taliglucerase alfa and the collaboration with Chiesi Farmaceutici for Elfabrio suggest a robust revenue-sharing model. Investors should evaluate the strategic importance of these partnerships and potential expansions into other markets or product lines.

4. **Market Sentiment:** The biotech sector can be volatile and reliant on news flow. Sentiment around Protalix will be influenced not just by financial results but also by the broader market context, including developments in competitor products and regulatory changes.

Ultimately, potential investors should maintain a balanced outlook, leveraging insights from the conference call and any guidance provided on future expectations. With a proven platform and promising pipeline, Protalix could present an attractive opportunity in the biotechnology space, but careful consideration is warranted prior to investment.